CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

肾功能下降预测大 B 细胞淋巴瘤 CAR-T 细胞治疗后重度细胞因子释放综合征

Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.

迈向个体化淋巴细胞清除：接受 CAR-T 细胞治疗患者的群体药代动力学氟达拉滨模型

Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.

使用抗体-细胞偶联技术的异体西妥昔单抗武装γδ T 细胞用于治疗表达 EGFR 的实体瘤

Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors.

这些发现支持 ACE2016 作为一种针对表达 EGFR 的癌症的现成γδ2 T 细胞疗法的临床潜力，在实体瘤疗法的开发中提供了特异性、可扩展性和安全性的结合。

EGFR 突变肺腺癌细胞来源外泌体 miR-651-5p 通过下调 BCL2 表达诱导 CD8+ T 细胞凋亡

EGFR-Mutant Lung Adenocarcinoma Cell-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression.

靶向磷脂酰丝氨酸的嵌合 TIM-4 受体修饰 T 细胞介导细胞毒性抗肿瘤反应及肿瘤相关抗原的吞噬摄取用于 T 细胞交叉呈递

Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-asso

T 和 NK 细胞淋巴瘤细胞系的生存不依赖于 ZAP-70

T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival.

来自大肠杆菌的全长重组抗体：生产、表征、效应功能（Fc）工程化与临床评价

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.